Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344752 | 1.00 | HAO1 (0.57) | HAO1KMT2AMAPTMEN1FAAH | |
| SCHEMBL31590747 | 0.98 | HAO1 (0.53) | HAO1KMT2AMAPTMEN1FAAH | |
| SCHEMBL11685972 | 0.91 | HAO1 (0.45) | HAO1KMT2AMAPTMEN1FAAH | |
| SCHEMBL27634581 | 0.89 | HAO1 (0.44) | HAO1KMT2AMAPTMEN1FAAH | |
| SCHEMBL2357081 | 0.86 | HAO1 (0.55) | HAO1KMT2AMAPTMEN1FAAH | |
| SCHEMBL7728958 | 0.85 | KMT2A (0.59) | HAO1KMT2AMAPTMEN1FAAH | |
| SCHEMBL2139864 | 0.83 | HAO1 (0.62) | HAO1KMT2AMAPTCES2CES1 | |
| SCHEMBL6269143 | 0.82 | CES2 (0.39) | HAO1KMT2AMEN1FAAHMAPK1 | |
| SCHEMBL23950131 | 0.82 | CES2 (0.64) | KMT2AMEN1FAAHMAPK1CES2 | |
| SCHEMBL23950441 | 0.82 | CES2 (0.64) | KMT2AMEN1FAAHMAPK1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009833-A1 | LIPID A MIMICS, METHODS OF PREPARATION, AND USES THEREOF | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2018-01-11 | — | — | US | disclosed |
| US-20150064240-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150064240-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. | 2015-03-05 | — | — | US | disclosed |
| US-8889616-B2 | MUC1 based glycolipopeptide vaccine with adjuvant | ONCOTHYREON INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8329639-B2 | MUC1 based glycolipopeptide vaccine with adjuvant | ONCOTHYREON INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329639-B2 | MUC1 based glycolipopeptide vaccine with adjuvant | ONCOTHYREON INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120282329-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282329-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8097593-B1 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7820627-B2 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820627-B2 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1549322-B1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC (US) | 2010-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282329-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | MUC1, LGALS3BP, ST3GAL3 | HAO1 4387/4885KMT2A 2399/4885MAPT 3311/4885 |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | SELPLG, STT3A, LY96 | HAO1 1956/4885KMT2A 1000/4885MAPT 3769/4885 |
| US-20180009833-A1 | LIPID A MIMICS, METHODS OF PREPARATION, AND USES THEREOF | CD14, LPAR4, TLR4 | HAO1 1934/4885KMT2A 409/4885MAPT 2267/4885 |
| US-20150064240-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | MUC1, LGALS3BP, ST3GAL3 | HAO1 4387/4885KMT2A 2399/4885MAPT 3311/4885 |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | MUC1, LGALS3BP, ST3GAL3 | HAO1 4387/4885KMT2A 2399/4885MAPT 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.